Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
509actual
Sites
223
Countries
Argentina, Australia, Austria +28
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-31 | actual | When the study began enrolling |
| Primary completion | 2025-01-29 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-26 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-23 | actual | When this record first appeared on the registry |
| Results posted | 2026-01-05 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-01-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer (SCLC)
Interventions
- Drug: Tarlatamab — also filed as AMG 757
- Drug: Lurbinectedin
- Drug: Topotecan
- Drug: Amrubicin
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-07-19 · 3.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-02-06 · 322 KB · SAP_001.pdf
Publications
- PMID 40454646 — cited as background
- PMID 42377743 — linked by the registry
- PMID 39530627 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed